BRTXHealthcare · BiotechnologyBRTX Stock Forecast: BioRestorative Therapies, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering BioRestorative Therapies, Inc. hold a median 12-month price target of $8 — +3554.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 21 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
BRTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores BioRestorative Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
BRTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +3554.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2024 | Roth MKM | Maintains | Buy | $15 → $18 |
| 12 June 2024 | Roth MKM | Maintains | Buy | — |
| 14 Aug 2023 | Roth MKM | Reiterates | Buy | — |
| 7 Dec 2022 | Roth Capital | Initiates | Buy | — |
| 28 Sept 2022 | Maxim Group | Initiates | Buy | — |
| 1 Dec 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRTX appears on the weeks it earns a place.
BRTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
BioRestorative Therapies, Inc. (BRTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.1×
- Price / sales
- 15.3×
- Price / book
- 1.8×
- EV / EBITDA
- −0.1×
Cheaper than 77% of US stocks
Cheaper than 11% of US stocks
Cheaper than 50% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- −7.3%
- Earnings growth (YoY)
- −7.3%
- Gross margin
- 68.1%
- Operating margin
- −14612.6%
- Net margin
- 93.4%
Higher than 18% of US stocks
Higher than 28% of US stocks
Higher than 81% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
- Return on equity
- −241.1%
- Return on assets
- −118.8%
- Dividend yield
- —
Higher than 6% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BRTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioRestorative Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BRTX stock
What is the BRTX stock price forecast for 2026-2027?
The 2 Wall Street analysts covering BioRestorative Therapies, Inc. have a median 12-month price target of $8, with estimates ranging from $1 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BRTX stock a buy right now?
Of the 2 analysts covering BioRestorative Therapies, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioRestorative Therapies, Inc. 8 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BRTX?
As at 21 Aug 2026, BioRestorative Therapies, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
Will BRTX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +3554.6% from the last close, and Ticker Nerd's factor model ranks BioRestorative Therapies, Inc. 8 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BRTX stock forecast for 2030?
No analyst covering BioRestorative Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $15 over the next 12 months.
How has BRTX stock performed over the past year?
BioRestorative Therapies, Inc. returned -85.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BioRestorative Therapies, Inc. do?
BioRestorative Therapies Inc. is a regenerative medicine company developing advanced stem cell-based therapies and products.
About BioRestorative Therapies, Inc.
BioRestorative Therapies Inc. is a regenerative medicine company developing advanced stem cell-based therapies and products. The company operates three primary business segments: its disc and spine program featuring BRTX-100, an autologous mesenchymal stem cell therapy designed to treat chronic lower back and neck pain from degenerative disc disease; its metabolic program called ThermoStem®, which utilizes brown adipose-derived stem cells to address obesity and metabolic disorders; and a commercial BioCosmeceutical platform offering cell-based secretome products containing exosomes, proteins, and growth factors engineered for aesthetic applications to reduce fine lines and wrinkles. BRTX-100 is currently in Phase 2 clinical trials and has received FDA Fast Track designation for chronic lumbar disc disease treatment. The company's approach leverages proprietary cell and tissue protocols using primarily adult stem cells collected from patients' own bone marrow or derived from other tissue sources. Founded by scientists and researchers focused on addressing unmet medical needs, BioRestorative combines clinical development with commercial product offerings in the emerging field of cell-based therapeutics and aesthetic medicine.
CEO Ms. Katharyn Field · 13 employees · United States · https://www.biorestorative.com